This blog answers all your concerns with research-backed insights, so read on to find out
Employer Coverage Trends Despite cost concerns, most large employers with existing GLP-1 coverage plan to continue it: 90% of large employers currently covering GLP-1s plan to maintain coverage in 2026 [13] 44% of employers with 500+ employees cover weight loss medications (up from prior years) [14] 64% of employers with 20,000+ employees offer coveragethe largest employers are most likely to cover [14] Cost impact: Covering GLP-1s may increase employer premiums by ~514%, driving some to add restrictions [15] Note: All 2026 timelines, pricing, and coverage expansions are subject to federal rulemaking, final CMS implementation, and individual state/employer decisions
Retatrutide dosing follows its own distinct schedule detailed in our retatrutide dose chart and retatrutide peptide dosage chart
Weight loss outcomes in the clinical trials showed diminishing returns between the 10 mg and 15 mg dose levels, with the jump from 10 to 15 mg producing a much smaller incremental benefit than the jump from 5 to 10 mg
Azelaic acid: Evidence-based update on mechanism of action and clinical application
doi: 10.2147/JPR.S55598